mbiomics

The company develops complex Live Biotherapeutic Products (LBPs) designed to treat severe and chronic diseases by restoring healthy microbial ecosystems. Utilizing a proprietary data science platform and strain library, they design and manufacture large microbial consortia through an in-house co-culturing process. Their technology includes precision analytics to track strain viability and a screening platform to nominate candidates for GMP production.